Aptar Pharma to Host Drug Delivery Insight Briefing at CPhI 2018
Guenter Nadler, director of Business Development at Aptar Pharma, will present an insight briefing on new drug-delivery trends in treating upper and lower respiratory tract issues on Wednesday, Oct. 9, 2018 at CPhI Worldwide.
Guenter Nadler, director of business development at Aptar Pharma, will present an insight briefing on new trends in treating upper and lower respiratory tract issues, including new respiratory technology platforms designed to market needs, on Tuesday, Oct. 9, 2018 in Madrid, Spain at CPhI Worldwide.
The discussion, “Portable Care for Your Respiratory Tract: Exploring New Technology Platforms,” will explore the necessity for more modern, portable treatments and offer insight into how to deliver such solutions to clients. Nadler’s briefing will take place at 12:30–1:00pm at InnoPack & P-MEC Theatre, Hall 4, stand 4F121.
As part of Aptar Pharma’s Consumer Health Care division, Nadler heads strategy and innovation for the company’s Cough & Cold business. He has 18 years of experience in drug delivery, including various technical and commercial roles.
Source: CPhI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
